NURIX THERAPEUTICS, INC. (NRIX)

Import this data to Google Sheets with:

=jivedata("NRIX","financials")

Full statements spill as a table. For one cell: =jivedata("NRIX","Revenue") or =jivedata("NRIX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

NURIX THERAPEUTICS, INC.

NRIX • CIK 0001549595

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	—	$54,549	$83,980	$701,936
Operating Income (Loss)	$-155,063	$-213,027	$-285,666	$289,657
Interest and Other Income	$11,115	$19,728	$21,969	$18,555
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-143,948	$-193,299	$-263,697	$308,212
Income Tax Expense (Benefit)	—	$270	$760	$13,335
Net Income (Loss) Attributable to Parent	$-143,948	$-193,569	$-264,457	$294,877
Weighted Average Number of Shares Outstanding, Basic	54,337,901	67,120,266	86,666,907	113,709,916
Research and Development Expense	$189,148	$221,632	$316,903	$334,073
General and Administrative Expense	$42,902	$45,944	$52,743	$78,206
Operating Expenses	$232,050	$267,576	$369,646	$412,279

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$54,627	$109,997	$246,960	$720,242
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	—	$499,586	$345,981	$328,013
Operating Lease, Right-of-Use Asset	$31,142	$28,139	$50,517	$48,631
Prepaid Expense and Other Assets, Current	$7,595	$9,804	$13,878	$35,437
Property, Plant and Equipment, Net	$16,808	$17,757	$22,490	$19,407
Assets, Current	$295,503	$619,387	$606,819	$1,103,692
Restricted Cash, Noncurrent	$901	$901	$968	$782
Other Assets, Noncurrent	$3,823	$3,159	$7,341	$7,954
Assets	$355,598	$669,343	$688,135	$1,195,298
Operating Lease, Liability, Noncurrent	$23,125	$20,289	$52,906	$62,091
Contract with Customer, Liability, Noncurrent	$45,022	$26,207	$10,011	$10,778
Liabilities	$155,105	$142,350	$149,388	$226,987
Accounts Payable, Current	$6,401	$11,482	$11,215	$32,984
Operating Lease, Liability, Current	$7,489	$8,014	$2,824	$3,241
Contract with Customer, Liability, Current	$48,098	$38,364	$17,580	$8,610
Liabilities, Current	$86,958	$95,854	$86,471	$130,742
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$49	$76	$102	$109
Additional Paid in Capital, Common Stock	$746,299	$1,265,536	$1,541,766	$1,598,540
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-655	$150	$105	$-210
Retained Earnings (Accumulated Deficit)	$-545,200	$-738,769	$-1,003,226	$-630,128
Stockholders' Equity Attributable to Parent	$200,493	$526,993	$538,747	$968,311
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000	500,000,000
Common Stock, Shares, Issued	48,718,552	75,870,718	101,807,484	109,200,394
Property, Plant and Equipment, Gross	$43,057	$52,259	$60,272	$62,875
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$26,249	$34,502	$37,782	$43,468
Depreciation, Depletion and Amortization, Nonproduction	$7,533	$9,318	$8,740	$6,590
Employee-related Liabilities, Current	$15,303	$16,631	$21,541	$20,269
Accrued Professional Fees, Current	$1,755	$1,615	$1,944	$1,826
Taxes Payable, Current	$30	$1,237	$1,059	$13,945
Other Liabilities, Current	$751	$2,275	$2,096	$1,485

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-143,948	$-193,569	$-264,457	$294,877
Net Cash Provided by (Used in) Operating Activities	$-81,365	$-172,584	$-249,465	$379,312
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-9,847	$55,370	$137,030	$641,618
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$55,528	$110,898	$247,928	$247,928
Depreciation, Depletion and Amortization, Nonproduction	$7,533	$9,318	$8,740	$8,710
Payments to Acquire Marketable Securities	—	$707,953	$455,688	$604,343
Share-based Payment Arrangement, Noncash Expense	$33,673	$33,929	$37,965	$40,655
Proceeds from Sale, Maturity and Collection of Investments	—	—	$617,543	$614,945
Accretion (Amortization) of Discounts and Premiums, Investments	$5,421	$11,288	$10,322	$6,342
Payments to Acquire Property, Plant, and Equipment	$8,401	$9,273	$14,002	$9,504
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	$-556	$-31	$-89	$-249
Net Cash Provided by (Used in) Investing Activities	$68,301	$-257,713	$147,853	$1,098
Operating Lease, Right-of-Use Asset, Amortization Expense	$6,121	$7,110	$10,116	$7,162
Other Noncash Income (Expense)	$0	$-286	$0	$0
Increase (Decrease) in Prepaid Expense and Other Assets	$-2,139	$459	$6,229	$13,297
Increase (Decrease) in Accounts Payable	$1,614	$5,209	$-630	$25,047
Increase (Decrease) in Contract with Customer, Liability	$19,513	$-28,549	$-36,980	$-21,780
Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised	$2,229	$2,132	$2,229	$2,735
IncreaseDecreaseInOperatingLeaseLiability	$-6,268	$-6,418	$-5,067	$-1,917
Proceeds from Issuance of Common Stock	$0	$289,763	$0	$18,004
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	$3,123	$11,816	$17,310	$20,339
Net Cash Provided by (Used in) Financing Activities	$3,217	$485,667	$238,642	$261,208
Capital Expenditures Incurred but Not yet Paid	$632	$1,643	$1,183	$-482
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$23,995	$4,107	$32,494	$2,765
Share-based Payment Arrangement, Amount Capitalized	$74	$14	$20	$20
Cash and Cash Equivalents, at Carrying Value	$54,627	$109,997	$246,960	$242,239
Restricted Cash, Noncurrent	$901	$901	$968	$1,035

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("NRIX","financials")

Full statements spill as a table. For one cell: =jivedata("NRIX","Revenue") or =jivedata("NRIX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.